11/4/2011

Life sciences firms secured $1.8 billion in venture capital investments during the third quarter with 170 deals, an 18% drop from the second quarter, according to a PricewaterhouseCoopers report. Tracy Lefteroff of PwC US pointed to regulatory challenges, difficulty with IPOs and equity market volatility as reasons.

Related Summaries